{"id":5068,"date":"2024-04-22T23:03:08","date_gmt":"2024-04-22T23:03:08","guid":{"rendered":"https:\/\/stuarttherapeutics.com\/?p=5068"},"modified":"2024-04-22T23:04:13","modified_gmt":"2024-04-22T23:04:13","slug":"stuart-therapeutics-inc-announces-upcoming-presentations-at-arvo-2024","status":"publish","type":"post","link":"https:\/\/stuarttherapeutics.com\/stuart-therapeutics-inc-announces-upcoming-presentations-at-arvo-2024\/","title":{"rendered":"Stuart Therapeutics, Inc. Announces Upcoming Presentations at ARVO 2024"},"content":{"rendered":"

\"Arvo<\/p>\n

Presentations at the OIS- and Ora-sponsored Dry Horizons meeting on\u00a0May 3<\/span>rd<\/sup>, at\u00a0OIS Retina on\u00a0May 4<\/span>th<\/sup>, and a poster at ARVO<\/p>\n

STUART, Fla.<\/span><\/span>,\u00a0April 19, 2024<\/span><\/span>\u00a0\/PRNewswire\/ — Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, today announced that the company will be presenting its latest research results at both the Association for Research in Vision and Ophthalmology annual meeting, and at two meetings sponsored by the Ophthalmology Innovation Source (OIS) in early May. Eric\u00a0Schlumpf, Stuart Therapeutics’ President and CEO, will be presenting at the Dry Horizons Symposium (co-sponsored by Ora, Inc.) on\u00a0Friday May 3<\/span>rd<\/sup>. His topic will be the company’s innovative dry eye disease program, currently in a Phase 3 trial. On\u00a0Saturday, May 4th<\/span>\u00a0he will be presenting the company’s latest pre-clinical results in\u00a0retinitis pigmentosa and in exudative retinal indications at the OIS Retina Meeting. Both of these meetings will be held at the Four Seasons Hotel in\u00a0Seattle<\/span>, Washington.\u00a0\"Stuart,<\/a><\/p>\n

\n
\n
\n
\n
Members of Stuart Therapeutics’ R&D team also co-authored \u00a0a poster presentation that is being presented by researchers from the <\/span>University of Rochester<\/span>\u00a0at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will take place from\u00a0<\/span>May 5-9, 2024<\/span>, in\u00a0<\/span>Seattle<\/span>. The poster presentation, entitled “Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation,” covers work done at the\u00a0<\/span>University of Rochester<\/span>\u00a0using Stuart Therapeutics’ proprietary collagen mimetic peptide platform to understand its efficacy in reversing the disruption of scleral collagen in the eye, a likely source of eye shape distortion in myopia. The study authors are\u00a0Aldo Tecse,\u00a0<\/span>Kaitlin Wozniak<\/span>,\u00a0<\/span>James German<\/span>,\u00a0<\/span>Alex McMullen<\/span>, Mark Buckley,\u00a0\u00a0<\/span>Robert Baratta<\/span>,\u00a0<\/span>Eric Schlumpf<\/span>,\u00a0<\/span>Brian J. Del Buono<\/span>,\u00a0<\/span>Michael Telias<\/span>, and\u00a0<\/span>Susana Marcos<\/span>.<\/span><\/figcaption><\/figure>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

About Stuart Therapeutics, Inc.<\/b>\u00a0
Stuart Therapeutics, founded in 2017 and based in\u00a0Stuart, Florida<\/span>, is the leader in the development of ECM-targeting therapeutics for disease treatment. Its platform technology,\u00a0PolyCol\u2122<\/sup><\/i><\/b>, is a portfolio of synthesized collagen mimetic peptides designed to specifically bind to and repair disease- or injury-damaged helical collagen structures. This activity results in both a repair of collagen structures and a restoration of homeostatic cell signaling, with positive effects on cell growth and proliferation and reduction in inflammation. These effects occur rapidly in treated tissues, and Stuart Therapeutics has extensive research results in a variety of refractive, anterior segment and posterior segment ophthalmic disease indications. For more information, visit\u00a0www.stuarttherapeutics.com<\/a>.<\/p>\n

CONTACT:\u00a0Eric Schlumpf<\/span>, President & CEO
<\/b>eric@stuarttherapeutics.com<\/a><\/b><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Presentations at the OIS- and Ora-sponsored Dry Horizons meeting on\u00a0May 3rd, at\u00a0OIS Retina on\u00a0May 4th, and a poster at ARVO STUART, Fla.,\u00a0April 19, 2024\u00a0\/PRNewswire\/ — Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, today announced that the company will…<\/p>\n","protected":false},"author":1,"featured_media":4311,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false},"categories":[33],"tags":[58,35],"_links":{"self":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/posts\/5068"}],"collection":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/comments?post=5068"}],"version-history":[{"count":3,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/posts\/5068\/revisions"}],"predecessor-version":[{"id":5072,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/posts\/5068\/revisions\/5072"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/media\/4311"}],"wp:attachment":[{"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/media?parent=5068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/categories?post=5068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stuarttherapeutics.com\/wp-json\/wp\/v2\/tags?post=5068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}